CNTA - CIK 0001847903
Centessa Pharmaceuticals plc trades as CNTA and has a market capitalization of $6.14 B, making it the #1247 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $15.00M and net income of -$197.53M. This page tracks Centessa Pharmaceuticals plc through 579 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| DEFM14A | - | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-05 |
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders – Centessa Pharmaceuticals
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences – Centessa Pharmaceuticals
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting – Centessa Pharmaceuticals
The largest companies sharing Centessa Pharmaceuticals plc's SEC industry classification (pharmaceutical preparations).
Centessa Pharmaceuticals plc (CNTA) has a market capitalization of $6.14 B as of 2026-06-10, ranking #1247 among US-listed companies.
Centessa Pharmaceuticals plc reported revenue of $15.00M for fiscal year 2025.
In its latest fiscal year Centessa Pharmaceuticals plc reported a net loss of $197.53M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.